US Department of Health and Human Services
Novo Nordisk agrees to lower certain drug prices in the US
The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid
Lilly announces agreement with US government to lower patient costs
The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels
What is willingness to pay? – Comparing price testing methodologies
Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to...
Ten participating drugmakers invited for further US Medicare drug price negotiations
ASPE revealed that the IRA is expected to save around 857,000 US women $1,000 or more in 2025
Drugmakers submit counteroffers to US Medicare pricing negotiations
New negotiated prices are set to be announced by 1 September 2024 and implemented in 2026
Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics
Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...
US government announces first ten drugs subject to Medicare pricing negotiations
The IRA programme is facing court challenges from leading drugmakers and industry groups
AstraZeneca latest to sue US government over Medicare drug price negotiation plan
The programme already faces court challenges from drugmakers and industry groups
Boehringer sues US government over Medicare drug price negotiation programme
The IRA allows Medicare to negotiate lower prices for selected medicines
Johnson & Johnson sues US government over Medicare drug price negotiation programme
The IRA allows Medicare to negotiate lower prices for a selected group of medicines
Merck sues US government over Medicare drug price negotiation programme
The drugmaker says the programme violates the First and Fifth Amendments to the US Constitution
The challenges of reimbursement and innovative pricing for cell and gene therapies
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...